Live Breaking News & Updates on Utah State University Antiviral Research Institute

Stay updated with breaking news from Utah state university antiviral research institute. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

SaNOtize's nasal spray eliminates 99% of Covid-19 virus


Industry > Industry monitor > Pharmaceuticals
22 April 2021
SaNOtize Research and Development Corp, a biotech company based in Vancouver, British Columbia, has developed and patented a Nitric Oxide Releasing Solution platform technology (NORS) to treat and prevent Covid-19 infections. 
Clinical trials indicated that SaNOtize’s Nitric Oxide Nasal Spray (NONS) represents a safe and effective antiviral treatment that could prevent the transmission of Covid-19, shorten its course, and reduce the severity of symptoms and damage in those already infected.
In a randomised, double-blind, placebo-controlled Phase 2 trial that evaluated 79 confirmed cases of Covid-19, SaNOtize’s early treatment for Covid-19 significantly reduced the level of SARS-CoV-2, including in patients with high viral loads. The average viral log reduction in the first 24 hours was 1.362, which corresponds to a decline of about 95 per cent. Within 72 hours, the viral load dropped by more than 99 p ....

New Zealand , United Kingdom , British Columbia , Chris Miller , Stephen Winchester , Gilly Regev , Sanotize Research , Development Corp , Utah State University Antiviral Research Institute , Nitric Oxide Releasing Solution , Nitric Oxide Nasal Spray , Blue Baby Syndrome , Utah State University , Antiviral Research , Omain B , புதியது ஜீலாந்து , ஒன்றுபட்டது கிஂக்டம் , பிரிட்டிஷ் கொலம்பியா , கிறிஸ் மில்லர் , ஸ்டீபன் வின்செஸ்டர் , வளர்ச்சி கார்ப் , நீலம் குழந்தை நோய்க்குறி , உட்டா நிலை பல்கலைக்கழகம் ,

Clinical trial confirms breakthrough treatment for COVID-19: Patients with a self-administered nasal spray found to have reduced SARS-CoV-2 viral load by more than 95% in infected participants within 24 hours


Clinical trial confirms breakthrough treatment for COVID-19: Patients with a self-administered nasal spray found to have reduced SARS-CoV-2 viral load by more than 95% in infected participants within 24 hours
Posted on
ADVERTISEMENT
Patients with a self-administered nasal spray application found to have reduced SARS-CoV-2 log viral load by more than 95% in infected participants within 24 hours of treatment, and by more than 99% in 72 hours
Trial concluded that treatment accelerated clearance of SARS-CoV-2 by a factor of 16-fold versus a placebo
Randomized, double-blind, placebo-controlled trial evaluated 79 confirmed cases of COVID-19, the majority heavily-infected with the UK variant
No adverse events were recorded in the group ....

United Kingdom General , United Kingdom , Stephen Winchester , Sanotize Research Development Corp , Utah State University Antiviral Research Institute , Surrey Pathology Services , Foundation Trust In Surrey , Emergency Use , Columbia Biotech , Development Corp , Nitric Oxide Nasal Spray , Consultant Medical Virologist , Chief Investigator , Blue Baby Syndrome , Seeking Emergency Use Authorization , Utah State University , Antiviral Research , ஒன்றுபட்டது கிஂக்டம் ஜநரல் , ஒன்றுபட்டது கிஂக்டம் , ஸ்டீபன் வின்செஸ்டர் , சர்ரே நோயியல் சேவைகள் , அடித்தளம் நம்பிக்கை இல் சர்ரே , அவசரம் பயன்பாடு , வளர்ச்சி கார்ப் , ஆலோசகர் மருத்துவ வைராலஜிஸ்ட் , தலைமை புலனாய்வாளர் ,

Clinical trial confirms breakthrough treatment for COVID-19


Clinical trial confirms breakthrough treatment for COVID-19
Randomized, double-blind, placebo-controlled trial evaluated 79 confirmed cases of COVID-19, the majority heavily-infected with the UK variant.
ADVERTISEMENT
Patients with a self-administered nasal spray application found to have reduced SARS-CoV-2 log viral load by more than 95% in infected participants within 24 hours of treatment, and by more than 99% in 72 hours
Trial concluded that treatment accelerated clearance of SARS-CoV-2 by a factor of 16-fold versus a placebo
Randomized, double-blind, placebo-controlled trial evaluated 79 confirmed cases of COVID-19, the majority heavily-infected with the UK variant
No adverse events were recorded in the group
Submission for Emergency Use in the UK and Canada for the treatment and prevention of COVID-19 is planned immediately ....

United Kingdom General , United Kingdom , Rob Wilson , Chris Miller , Stephen Winchester , Gilly Regev , Sanotize Research Development Corp , Pt Mag Campaign , Utah State University Antiviral Research Institute , Surrey Pathology Services , Foundation Trust In Surrey , Emergency Use , Columbia Biotech , Development Corp , Nitric Oxide Nasal Spray , Consultant Medical Virologist , Chief Investigator , Blue Baby Syndrome , Seeking Emergency Use Authorization , Utah State University , Antiviral Research , Chief Science Officer , Call Willie , ஒன்றுபட்டது கிஂக்டம் ஜநரல் , ஒன்றுபட்டது கிஂக்டம் , கொள்ளை வில்சன் ,